Pharmacokinetic aspects of the anti-epileptic drug substance vigabatrin: focus on transporter interactions
作者： Martha Kampp Nøhr , Sidsel Frølund , René Holm , Carsten Uhd Nielsen
DOI: 10.4155/TDE.14.55
关键词:
摘要: Drug transporters in various tissues, such as intestine, kidney, liver and brain, are recognized important mediators of absorption, distribution, metabolism excretion drug substances. This review gives a current status on the transporter(s) mediating properties anti-epileptic substance vigabatrin. For orally administered drugs, like vigabatrin, absorption from intestine is prerequisite for bioavailability. Therefore, involved intestinal vigabatrin vitro vivo discussed detail. Special focus contribution proton-coupled amino acid transporter 1 (PAT1) absorption. Furthermore, an overview pharmacokinetic parameters across different species drug–food drug–drug interactions involving
future-science.com
sci-hub.se 参考文章(76)
Silke Grigat, Christian Fork, Markus Bach, Stefan Golz, Andreas Geerts, Edgar Schömig, Dirk Gründemann, The Carnitine Transporter SLC22A5 Is Not a General Drug Transporter, but It Efficiently Translocates Mildronate Drug Metabolism and Disposition. ,vol. 37, pp. 330- 337 ,(2009) , 10.1124/DMD.108.023929
Jesper Erdal, Lennart Gram, Jørgen Alving, Wolfgang Löscher, Changes in plasma GABA concentration during vigabatrin treatment of epilepsy: a prospective study. Epilepsy Research. ,vol. 34, pp. 145- 150 ,(1999) , 10.1016/S0920-1211(98)00112-0
Matthias A. Hediger, Michael F. Romero, Ji-Bin Peng, Andreas Rolfs, Hitomi Takanaga, Elspeth A. Bruford, The ABCs of solute carriers: physiological, pathological and therapeutic implications of human membrane transport proteins Pflügers Archiv: European Journal of Physiology. ,vol. 447, pp. 465- 468 ,(2004) , 10.1007/S00424-003-1192-Y
Michael Boll, Martin Foltz, Catriona M. H. Anderson, Carmen Oechsler, Gabor Kottra, David T. Thwaites, Hannelore Daniel, Substrate recognition by the mammalian proton-dependent amino acid transporter PAT1. Molecular Membrane Biology. ,vol. 20, pp. 261- 269 ,(2003) , 10.1080/0968768031000100759
Philip N Patsalos, Emilio Perucca, Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs The Lancet Neurology. ,vol. 2, pp. 347- 356 ,(2003) , 10.1016/S1474-4422(03)00409-5
J. F. Hoke, S. L. Durham, Teng-Man Chen, Pharmacokinetics and metabolism of vigabatrin following a single oral dose of [14C]vigabatrin in healthy male volunteers. Drug Metabolism and Disposition. ,vol. 21, pp. 480- 484 ,(1993)
Sidsel Frølund, Louise Langthaler, Morten A. Kall, René Holm, Carsten Uhd Nielsen, Intestinal drug transport via the proton-coupled amino acid transporter PAT1 (SLC36A1) is inhibited by Gly-X(aa) dipeptides. Molecular Pharmaceutics. ,vol. 9, pp. 2761- 2769 ,(2012) , 10.1021/MP300345E
Mumford Jp, A profile of vigabatrin. The British journal of clinical practice. ,vol. 61, pp. 7- 9 ,(1988)
Bente Steffansen, Carsten Uhd Nielsen, Birger Brodin, Carrier-mediated transport kinetics Pharmaceutical Press. ,(2010)
Robert D. Cary Elwes, Colin D. Binnie, Clinical pharmacokinetics of newer antiepileptic drugs. Lamotrigine, vigabatrin, gabapentin and oxcarbazepine. Clinical Pharmacokinectics. ,vol. 30, pp. 403- 415 ,(1996) , 10.2165/00003088-199630060-00001